CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0615 (clinicaltrials.gov NCT No: NCT01261312)
Title:A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Principal Investigator:Hagop Kantarjian
Treatment Agent:SGI-110
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of SGI-110 when given on different schedules in patients with MDS or AML. The
safety of this drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:SGI-110
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Astex Pharmaceuticals, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults